Mannkind's Customers Performance

Name: Mannkind Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

MNKD

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


MNKD's Source of Revenues		During the corresponding time, Mannkind Corporation recorded a revenue increase by 42.92 % year on year, sequentially revenue grew by 21.3 %. While revenue at the Mannkind Corporation's corporate clients • List of MNKD Customers

for the same period Mannkind Corporation recorded revenue increase by 42.92 % year on year, sequentially revenue grew by 21.3 %.

• List of MNKD Customers

Mannkind's Business Units


Product	41.08 %	of total Revenue
License and Service	53.52 %	of total Revenue
Royalty	59.54 %	of total Revenue
All Other Segments	182.44 %	of total Revenue
Product Revenue	116.57 %	of total Revenue
Service	6.33 %	of total Revenue
Other agreements UT CSA	2.19 %	of total Revenue

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Mannkind's Comment on Sales, Marketing and Customers

News about Mannkind Corporation Contracts

INHALE-3 Study Demonstrates Superiority of Inhaled Insulin in Treating Type 1 Diabetes Implications for Mannkind Corp...

CSIMarket.com is pleased to present an analysis of the recently concluded INHALE-3 study, which compared the efficacy of inhaled insulin with usual care in the treatment of Type 1 Diabetes (T1D). Additionally, we will discuss the impact of this study on Mannkind Corporation, a leading pharmaceutical company specializing in inhalable insulin solutions. The INHALE-3 study, presented at the American Diabetes Association s 84th Scientific Sessions, revealed a remarkable outcome favoring inhaled insulin in a head-to-head comparison with standard care for T1D patients. This groundbreaking research demonstrated the potential benefits of inhaled insulin in improving glycemic control and simplifying treatment regi...

MannKind Expands RandD Presence in Boston and Enhances Inhalation Technology P...

MannKind to Establish Boston-Area Research and Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction with Pulmatrix Valencia, Calif., October XX, 2023 - MannKind Corporation, a company at the forefront of developing innovative inhalation technologies, today announced a strategic transaction with Pulmatrix, Inc. to expand its Research and Development (RandD) capabilities and its cutting-edge portfolio of dry powder inhalation technology. This move will significantly bolster MannKind s presence in the highly dynamic Boston area, a region known for its concentration of biotech and pharmaceutical RandD activities. Strategic Acquisition to Solidify Position in Inhalation T...

MannKind Advancing Research in Pulmonary Fibrotic Diseases and Pediatric Diabetes with Study on Nintedanib DPI (MNKD-201) and Completion of INHALE-1 Trial Enrollment

MannKind, a leading biopharmaceutical company, is making significant strides in the treatment of pulmonary fibrotic diseases and pediatric diabetes. The company recently announced its plans to proceed with a Phase 1 study of nintedanib DPI (MNKD-201) for pulmonary fibrotic diseases, specifically focusing on idiopathic pulmonary fibrosis (IPF). This groundbreaking study aims to evaluate the efficacy and safety of nintedanib DPI as a potential treatment option for patients suffering from this devastating lung condition.IPF, a chronic and progressive form of lung disease, affects thousands of individuals worldwide. The condition leads to the scarring and stiffening of lung tissue, resulting in respiratory diffi...

MNKD's Stock Performance relative to it's Customers

MNKD's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Mannkind Corporation	1,162.56	360.78	-23.91	592
SUBTOTAL	0.00	0.00	0.00	-

Sources: Mannkind Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Mannkind Corporation’s corporate clients.
For your research, we’ve provided 9 tables on Mannkind Corporation corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.